Carlos Briceño

1 month ago | huntingtonsdiseasenews.com | Lindsey Shapiro |Marisa Wexler |Carlos Briceño

Daily treatment with Ingrezza (valbenazine) eases the jerky, involuntary movements known as chorea across different body regions in people with Huntington’s disease, according to new data analyses from the KINECT-HD trial. The primary analyses from the Phase 3 KINECT-HD study (NCT04102579) showed that the oral therapy overall reduced chorea severity. The new analyses show that the benefits could be seen across individual body regions, with the most pronounced improvements in the arms and legs.

1 month ago | huntingtonsdiseasenews.com | Lindsey Shapiro |Carlos Briceño |Steve Bryson |Marisa Wexler

One-year results from the Phase 2 PIVOT-HD clinical trial testing PTC Therapeutics’ Huntington’s disease treatment PTC518 are expected in the second quarter. That’s according to an update from PTC, which also noted that in a December meeting with the U.S. Food and Drug Administration (FDA), the agency requested additional trial data to support the company’s plans to seek PTC518’s accelerated approval. The company expects findings from PIVOT-HD (NCT05358717) to help address that request.

2 months ago | huntingtonsdiseasenews.com | Marisa Wexler |Lindsey Shapiro |Carlos Briceño |Steve Bryson

Specific genes involved in repairing mismatched DNA contribute to the development of Huntington’s disease by driving fast somatic CAG repeat expansion — a phenomenon in which Huntington’s-causing mutations grow, or expand, during a person’s lifetime, scientists report. Their study, done in a mouse model of Huntington’s, showed that targeting these genes prevented further somatic CAG repeat expansion and the formation of the mutant huntingtin protein clumps that ultimately drive neurodegeneration.

2 months ago | huntingtonsdiseasenews.com | Carlos Briceño

Columnist Carlos Briceño argues that the Genetic Information Nondiscrimination Act falls short in protecting people with genetic conditions.

Jan 28, 2025 | huntingtonsdiseasenews.com | Lindsey Shapiro |Carlos Briceño |Katherine Poinsatte |Steve Bryson

Subtle biomarkers of neurodegeneration are evident decades before the onset of overt Huntington’s disease symptoms in people with disease-causing mutations, a study found. Somatic CAG repeat expansions — a phenomenon in which Huntington’s-causing mutations grow, or expand, during a person’s lifetime — were associated with these neurodegenerative biomarkers.